BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 195 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $8 | -100.0% | 67,300 | -27.3% | 0.00% | -95.2% |
Q3 2022 | $314,000 | -1.9% | 92,634 | +9.8% | 0.02% | +31.2% |
Q2 2022 | $320,000 | -53.4% | 84,357 | -34.9% | 0.02% | -42.9% |
Q1 2022 | $686,000 | -74.3% | 129,536 | -61.4% | 0.03% | -61.6% |
Q4 2021 | $2,671,000 | +15.6% | 335,776 | +33.0% | 0.07% | -2.7% |
Q3 2021 | $2,311,000 | +311.2% | 252,553 | +107.5% | 0.08% | +341.2% |
Q2 2021 | $562,000 | +152.0% | 121,707 | +13.1% | 0.02% | +54.5% |
Q1 2021 | $223,000 | -50.6% | 107,600 | -58.6% | 0.01% | -15.4% |
Q4 2020 | $451,000 | +3369.2% | 259,600 | +1004.7% | 0.01% | +1200.0% |
Q3 2020 | $13,000 | -76.8% | 23,500 | -68.3% | 0.00% | -66.7% |
Q2 2020 | $56,000 | +522.2% | 74,100 | +60.4% | 0.00% | +200.0% |
Q1 2020 | $9,000 | -25.0% | 46,200 | +69.9% | 0.00% | 0.0% |
Q4 2019 | $12,000 | – | 27,200 | +35.3% | 0.00% | – |
Q2 2019 | $0 | -100.0% | 20,100 | -60.9% | 0.00% | -100.0% |
Q4 2016 | $326,000 | – | 51,468 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |